tiprankstipranks
The Fly

Nyxoah reports Q4 revenue EUR 1.3M

Nyxoah reports Q4 revenue EUR 1.3M

“2024 was a transformative year for Nyxoah (NYXH). We reported best-in-class outcomes from our DREAM pivotal study, completed our PMA submission with the FDA for Genio, and built a world-class U.S. commercial organization,” commented Olivier Taelman, Nyxoah’s CEO. “We believe an approval is still expected by the end of the first quarter, and we look forward to launching this innovative therapy to the millions of Americans suffering from moderate to severe OSA.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com